Platelet function in 22q11.2 deletion syndrome

Gepubliceerd: 25-03-2021 Laatst bijgewerkt: 19-03-2025

1) there will be a significant difference in platelet function and bleeding risk between adults with 22q11.2DS and healthy controls 2) there will be differences in RNA and metabolites between 22q11.2DS with schizophrenia and without schizophrenia as...

Ethische beoordeling	Niet van toepassing
Status	Werving nog niet gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON24347

Bron
NTR

Verkorte titel
TBA

Aandoening

22q11.2 deletion syndrome, schizophrenia, thrombocytopenia

Ondersteuning

Primaire sponsor: None
Overige ondersteuning: None

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

- Bleeding risk score (ISTH-BAT questionnaire).
- Complete blood count.

- Platelet aggregation and (functional) flowcytometry.
- Flow chamber results with respect to platelet binding to coated surfaces (in bright field view), P-selectin expression, fibrinogen binding and phosphatidyl serine (PS) exposure.
- Global scale quantitative and qualitative RNA differences (transcriptomics).
- Global scale quantitative metabolite differences (metabolomics).

Toelichting onderzoek

Achtergrond van het onderzoek

Background: 22q11.2 Deletion syndrome (22q11.2DS) is caused by recurrent heterozygous microdeletions on chromosome 22q11.2, encompassing up to 90 genes. This syndrome is characterized by a multi-organ disorder with a variable phenotype, including intellectual disability, cognitive deterioration, schizophrenia, early-onset Parkinson's disease, recurrent epistaxis, and macrothrombocytopenia; ~30% of the adults with 22q11.2DS have thrombocytopenia (<150,000 platelets per mL). Schizophrenia occurs in ~25% of individuals with 22q11.2DS, and ~1-2% of individuals with schizophrenia in the general population have the 22q11.2DS. Approximately 40% of the individuals with 22q11.2DS has intellectual disability.
Importantly, platelets have a critical role in hemostasis. Also, they show similarities to neurons concerning several morphologic and biochemical characteristics, are easier to investigate, and may therefore serve as a window to the brain.
Only a limited number of studies has investigated bleeding risk and platelet function in 22q11.2DS, and those who did only included children. Some of these studies indicated impaired platelet function and increased bleeding risk, and one reported a negative correlation between platelet count and age, which may suggest that platelet-associated problems increase with increasing age.

Aim: The combination of bleeding risk score and platelet function analysis with platelet transcriptomics and metabolomics may: 1) provide insight into bleeding risk, which is of direct relevance for patient care, and 2) provide insight in mechanisms underlying neurodevelopmental and neuropsychiatric disorders, like schizophrenia, that are frequently seen in 22q11.2DS.

Methods: we will include 40 adults with 22q11.2DS (20 with schizophrenia, 20 without schizophrenia) and 20 healthy controls. All participants will be assessed once (1 our in total), this includes blood drawl and completing a bleeding risk questionnaire.

Doel van het onderzoek

1) there will be a significant difference in platelet function and bleeding risk between adults with 22q11.2DS and healthy controls
2) there will be differences in RNA and metabolites between 22q11.2DS with schizophrenia and without schizophrenia as well as between 22q11.2DS in general and healthy controls

Onderzoeksopzet

Cross-sectional, only one assessment

Onderzoeksproduct en/of interventie

Blood drawl and ISTH-BAT questionnaire

Contactpersonen

Publiek

Maastricht University and 's Heeren Loo
Emma von Scheibler

+31 6 30929018

Wetenschappelijk

Maastricht University and 's Heeren Loo
Emma von Scheibler

+31 6 30929018

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- 16 years or older.
- signed informed consent.

Adults with 22q11.2DS
- molecularly confirmed 22q11.2 deletion syndrome.
- Mentally competent (ability to give informed consent) and aged 16 years and older or, in case the individual is mentally incompetent aged 16 years and older, consent will be given by the legally authorized representative of the subject.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

- The presence of any malignancy.
- Use of antiplatelet or anticoagulant drugs within the last two weeks prior to the study.
- Use of anti-inflammatory drugs within the last two weeks prior to the study.
- Medical history of auto-immune thrombocytopenia

Specific for healthy controls:
- A medical history of thrombocytopenia (<150.000 platelets per mL).
- Increased bleeding risk, defined as a diagnosed bleeding disorder.
- Metabolic disorder.

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Anders
Toewijzing:	N.v.t. / één studie arm
Blindering:	Open / niet geblindeerd
Controle:	Geneesmiddel

Deelname

Nederland

Status:	Werving nog niet gestart
(Verwachte) startdatum:	01-05-2021
Aantal proefpersonen:	60
Type:	Verwachte startdatum

Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)

Wordt de data na het onderzoek gedeeld: Nog niet bepaald

Ethische beoordeling

Niet van toepassing

Soort: Niet van toepassing

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 55192
Bron: ToetsingOnline
Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL9363
CCMO	NL75078.068.21
OMON	NL-OMON55192

Resultaten